Home » Authors » Cormac Sheridan

Cormac Sheridan

Articles

ARTICLES

Crucell Getting STAR Technology Through ChromaGenics Purchase

March 17, 2004

By Cormac Sheridan

BioXell Brings In EUR7.3M For R&D Through Grant, Loan

March 17, 2004

By Cormac Sheridan

Medivir Seeking SEK322M In Discounted Rights Issue

March 17, 2004

By Cormac Sheridan

BioTie Gains Ground On News Of Bioheparin Deal With Aventis

March 10, 2004

By Cormac Sheridan

Basilea Moving Infection Drug Into Phase III, Launching IPO

March 10, 2004

By Cormac Sheridan

BioTie Gains Ground On News Of Bioheparin Deal With Aventis

March 10, 2004

By Cormac Sheridan

Basilea Moving Infection Drug Into Phase III, Launching IPO

March 10, 2004

By Cormac Sheridan

Active Biotech Cuts Work Force; Focus Now On Current Portfolio

March 3, 2004

By Cormac Sheridan

Active Biotech Cuts Work Force; Focus Now On Current Portfolio

March 3, 2004

By Cormac Sheridan

Borean Pharma Brings In ApoA-I Project Via Proteopharma Buyout

Feb. 25, 2004

By Cormac Sheridan

View All Articles by Cormac Sheridan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...